Alamar Biosciences Inc(ALMR) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
October 8 at 7:39 PM ET (Korea 10/9 08:39)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | - | Insider Own | 48.36% | Shs Outstand | 69.4M | Perf Week | -20.18% |
| Market Cap | 1.80B | Forward P/E | - | EPS next Y | 45.32% | Insider Trans | 1.42% | Shs Float | 35.8M | Perf Month | -10.53% |
| Enterprise Value | 1.60B | PEG | - | EPS next Q | -0.21 | Inst Own | 24.83% | Short Float | 5.92% | Perf Quarter | -8.83% |
| Income | - | P/S | - | EPS this Y | -480% | Inst Trans | 72.1% | Short Ratio | 5.37 | Perf Half Y | - |
| Sales | - | P/B | 5.75 | EPS next 5Y | -21.86% | ROA | - | Short Interest | 2.12M | Perf YTD | 14.65% |
| Book/sh | 4.51 | P/C | 7.19 | EPS past 3/5Y | - | ROE | - | 52W High | -34.59% ($39.61) | Perf Year | - |
| Cash/sh | 3.6 | P/FCF | - | Sales past 3/5Y | - | ROIC | - | 52W Low | 37.49% ($18.84) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | - | Gross Margin | - | Volatility(W/M) | 14.77% 9.11% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 2.93 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 10.23 | EPS Q/Q | - | Profit Margin | - | RSI (14) | 38 | Recom | 1.4 |
| Dividend Gr. 3/5Y | - | Current Ratio | 11.85 | Sales Q/Q | - | SMA20 | -18.71% ($31.87) | Beta | - | Target Price | $35.4 |
| Payout | - | Debt/Eq | 0.16 | Earnings | 2026/8/10 | SMA50 | -17.07% ($31.24) | Rel Volume | 2.42 | Prev Close | $27.77 |
| Employees | 222 | LT Debt/Eq | 0.16 | EPS/Sales Surpr. | 28.55% 13.69% | SMA200 | -2.95% ($26.7) | Avg Volume(3M) | 0.40M | Price | $25.91 |
| IPO | 2026/4/17 | Option/Short | No/Yes | Trades | 10124 | Volume | 955,766 | Change | -6.7% |
🔬 Alamar Biosciences is a proteomics company that measures ultra-low-abundance protein biomarkers in biofluids such as blood with extremely high sensitivity. Leveraging its proprietary NULISA technology and the ARGO measurement system, the company targets the immunology, neurology, and oncology research markets and supplies testing kits—including neurodegenerative disease panels—along with analysis software.
Over the past 1 year, roughly in the middle
35% below its 1-year high.
Traded more than usual That is 242% of its average volume.
Growth has stalled
Earnings are expected to grow by -480.0% this year.
Tap to view numbers
Not enough quarters to judge yet
Only 1 quarter(s) reported, so no grade yet.
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Long-term returns are roughly flat
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 24.8%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #31 of 143 in the industry
Based on market cap of $2B.
INSP#29 Inspire Medical Systems Inc $2B PER 14.5 
ESTA#30 Establishment Labs Holdings Inc $2B PER - ALMR#31 Alamar Biosciences Inc $2B PER - 
NVCR#32 NovoCure Ltd $2B PER - 
ATEC#33 Alphatec Holdings Inc $2B PER - 
FAQ
What kind of company is ALMR?
ALMR belongs to the Healthcare sector and operates in the Medical Devices industry.
What is the market cap of ALMR?
The market cap of ALMR is approximately $1.8B, ranking 2,151 within its sector.
What is the 52-week high and low for ALMR?
ALMR has recorded a 52-week high of $39.61 and a low of $18.84.
